Scientific Initiatives

Stand Up To Cancer’s Dream Teams represent a revolutionary approach to cancer research, fostering collaboration among top researchers from different institutions and disciplines. Since its inception in 2008, the Dream Team model has broken down barriers in the scientific community, encouraging researchers to work together instead of in competition. This collaborative method accelerates the development of groundbreaking treatments, moving therapies from the lab to patients more swiftly and effectively.

Dream Teams are composed of experts across various fields, including oncology, molecular biology, immunology, data science, and engineering. This integration of perspectives enhances the understanding of cancer’s complexities, leading to more effective and personalized treatment approaches. By leveraging collective expertise, these teams have significantly advanced research in areas such as:

• Cancer growth modeling and drug resistance: Using computational and AI techniques to understand and overcome treatment challenges.
• New drug combinations: Spearheading early-stage clinical trials for novel therapies.

SU2C remains committed to forming new Dream Teams to tackle emerging challenges in cancer research. Future projects are set to expand on early detection efforts and pioneering therapies that prevent cancer progression before it fully develops.

SU2C Convergence^® is an innovative program that integrates expertise from diverse scientific fields, including medical, physical, and computational sciences. Launched to address complex questions about cancer biology, this approach has propelled research beyond traditional boundaries, enhancing the understanding of how cancers grow, resist treatment, and interact with the immune system.

By bringing together professionals from different scientific backgrounds, SU2C Convergence addresses big questions in cancer research that no single discipline could tackle alone. The result is a unique and holistic approach that:

• Models complex cancer growth: Using data science and computational methods, researchers can simulate how different types of cancer respond to various treatments.
• Explores immune system interactions: Studies under SU2C Convergence have explored how cancer cells and the immune system interact, opening new avenues for immunotherapy and treatment resistance solutions.

These collaborations have led to significant insights, allowing researchers to develop more precise and effective therapies that can be rapidly adapted to clinical use.

The SU2C Convergence initiative will continue to push the boundaries of interdisciplinary collaboration. New projects aim to enhance early detection techniques that could save countless lives.

SU2C Catalyst^® is a groundbreaking initiative that propels cancer treatment development by fostering innovative collaborations between researchers, pharmaceutical companies, and device manufacturers. By rapidly exploring new uses and combinations of existing drugs and therapies, SU2C Catalyst expedites the early-stage clinical trial process, bringing promising treatments to patients faster than traditional methods.

SU2C Catalyst is designed to address the urgent need for effective cancer treatments by leveraging existing drugs and technologies in novel ways. The program focuses on:

• Repurposing and Combining Treatments: By testing combinations of existing drugs, SU2C Catalyst identifies potential new treatment protocols more quickly, reducing the time and costs associated with developing entirely new drugs.
• Collaborative Environment: The program brings together pharmaceutical companies, academic researchers, and clinical institutions to create a collaborative space that accelerates the translation of research into clinical applications.

These strategic collaborations have led to breakthroughs that advance the standard of care and introduce new hope for patients battling cancer.

As SU2C looks to the future, the SU2C Catalyst initiative will continue to push the boundaries of collaboration by bridging the gap between the pharmaceutical industry and academic research laboratories. New partnerships will delve deeper into cancer-immune interactions, generate new devices for early detection, and ultimately pave the way for novel treatment regimens for patients that need them the most.